-
Take a Pain Check Foundation features a new blog highlighting Augurex’s 14-3-3eta biomarker.
-
The blog post explores how biomarkers improve diagnosis and personalized care in rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA).
Vancouver, Canada – June 5, 2025 – Augurex Life Sciences, a leader in autoimmune diagnostics, today announced that its 14-3-3eta biomarker was recently featured in a blog by Take a Pain Check Foundation, an organization dedicated to empowering youth with rheumatic diseases.
The Healthcare Perspectives article, “Biomarkers in Arthritis: Helping You and Your Doctor See the Full Picture,” explores how biomarkers like 14-3-3eta are transforming the detection and monitoring of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). These tools provide clinicians and patients with clearer insights into disease detection and progression, enabling more informed, personalized treatment decisions.
Arthritis, including RA and JIA, is a chronic autoimmune condition characterized by joint inflammation that can significantly impact quality of life, especially in young people. Biomarkers such as 14-3-3eta complement traditional tests by offering measurable data to detect disease earlier, track progression, and support tailored care to improve long-term outcomes.
Augurex is proud to partner with patient advocacy organizations like Take a Pain Check Foundation to raise awareness and improve outcomes for those living with rheumatic diseases.
Read the full article here: Biomarkers in Arthritis: Helping You and Your Doctor See the Full Picture
About Augurex
Augurex is a commercial-stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test, which detects the 14-3-3eta protein, is available as JOINTstat® in Canada and Great Britain, and is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. The analyte-specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex ASRs, available as SPINEstat™ in Canada and Great Britain, expands Augurex’s biomarker-informed diagnostic autoimmune solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which, if untreated, can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn, and X.
Media Contact
Nima Mazinani
(604) 674-8231
media@augurex.com